AUG 14, 2019 4:20 PM PDT

New Cannabis Research: UC Davis Teams up With Biopharmaceutical Research Company and DEA

WRITTEN BY: Julia Travers

While cannabis laws move forward, research to back them up lags behind. A new multi-sector research endeavor will aim to bring cannabis sciences more up-to-date.

The University of California, Davis (UC Davis) is joining forces with Biopharmaceutical Research Company (BRC), a pharmaceutical company that is federally compliant and registered with the Drug Enforcement Administration (DEA). Together, they will study biological and chemical cannabis profiles, in hopes of benefitting health care providers, lawmakers, law enforcement professionals and scientists who engage with cannabis in their work. The compositions of tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids will take center-stage in this endeavor.

"While cannabis is already available for medicinal and recreational use in a majority of states, cannabis research has long struggled to keep pace with the law," Gail Taylor, professor and chair of the Department of Plant Sciences at UC Davis, said, according to EurekAlert. Gail hopes she and her team will be able to help regulators better understand and manage the possible benefits and risks of cannabis.

Research foci and goals will include identifying and testing the best methods for cannabis sativa standardization; interactions between the plant and pests, and microbes and pathogens, in relation to crop management strategies; and regulation, treatment applications and prescription practices for the substance.

BRC’s mission is to explore how cannabis can help U.S. patients, especially veterans facing various afflictions and challenges. George Hodgin, founder and CEO of BRC, said, “The BRC team is eager to support UC Davis in this research endeavor, and to help lawmakers and regulators better understand the science of cannabis, so stakeholders can more effectively make policy and health decisions."

 

In related news, UC Davis is also launching a Cannabis and Hemp Research Center. It will open later in 2019 and will offer and conduct research, educational exchange, conferences and seminars. It will engage policymakers on these topics and provide seed funding, as well.

The center “will also provide a centralized resource to ensure compliance with current laws and policies,” Cindy Kiel, executive associate vice chancellor for research administration for the UC Davis Office of Research, said.

Article source: EurekAlert

About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech, conservation and the arts. She enjoys solutions journalism. Find more of her work at jtravers.journoportfolio.com.
You May Also Like
OCT 04, 2019
Cannabis Sciences
OCT 04, 2019
THC Found in Almost Half of Popular Hemp-CBD Products
Many cannabidiol (CBD) products are assumed or advertised to be free, or mostly free, of Tetrahydrocannabinol (THC). A new study finds this is not always t...
NOV 22, 2019
Cannabis Sciences
NOV 22, 2019
Feds Warn CBD Companies About Health Claims, Demand Response
Two federal agencies are alerting CBD companies that their marketing claims are illegal. The FTC and FDA sent out letters to several CDB companies deemed t...
NOV 22, 2019
Health & Medicine
NOV 22, 2019
Federal Government Weighs in on Marijuana and Opioid Addiction
The U.S. government is weighing in on the hot topic of whether or not medical marijuana is a successful tool in treating opioid addiction by barring the us...
FEB 07, 2020
Health & Medicine
FEB 07, 2020
Could False Cannabis Information Online Be Harmful To Public Health?
Under federal law, cannabis is illegal and considered a class 1 drug, meaning that it is perceived to have no medical value, with a high potential for user...
FEB 11, 2020
Cannabis Sciences
FEB 11, 2020
Traffic Light System Best Way to Label Cannabis Edibles
Cannabis products have become increasingly popular. Yet, as they are still relatively new to the market, research has found that most consumers don’t...
MAR 12, 2020
Cannabis Sciences
MAR 12, 2020
In New Jersey, Medical Marijuana Patients Can't Be Fired for Drug Tests
Thirty-three states, Washington D.C., Guam, Puerto Rico and the U.S. Virgin Islands now have a comprehensive, publicly available medical marijuana program....
Loading Comments...